New Histamine H<sub>3</sub>-Receptor Ligands of the Proxifan Series: Imoproxifan and Other Selective Antagonists with High Oral in Vivo Potency
作者:Astrid Sasse、Bassem Sadek、Xavier Ligneau、Sigurd Elz、Heinz H. Pertz、Peter Luger、C. Robin Ganellin、Jean-Michel Arrang、Jean-Charles Schwartz、Walter Schunack、Holger Stark
DOI:10.1021/jm000971p
日期:2000.8.1
Histamine H(3)-receptor antagonists of the proxifan series are described. The novel compounds possess a 4-(3-(phenoxy)propyl)-1H-imidazole structure and various functional groups, e.g., an oxime moiety, on the phenyl ring. Synthesis of the novel compounds and X-ray crystallography of one highly potent oxime derivative, named imoproxifan (4-(3-(1H-imidazol-4-yl)propyloxy)phenylethanone oxime), are described
描述了proxifan系列的组胺H(3)-受体拮抗剂。该新型化合物具有4-(3-(苯氧基)丙基)-1H-咪唑结构和在苯环上的各种官能团,例如肟部分。描述了新型化合物的合成和一种名为imoproxifan(4-(3-(1H-咪唑-4-基)丙氧基)苯乙酮肟)的高效肟衍生物的X射线晶体学。大多数标题化合物在体内以及在口服给药后的小鼠CNS体内在组胺H(3)-受体测定中均具有很高的拮抗剂效力。讨论了构效关系。在对大鼠大脑皮层突触小体的功能测定中,Imoproxifan表现出亚纳摩尔效价(K(i)= 0.26 nM)。在体内,莫洛昔芬以0.034 mg / kg po的ED(50)升高中心N(tau)-甲基组胺水平。